AstraZeneca in preclinical development for Brilinta reversal agent
CORRECTION: The original version of this article stated that Effient was co-developed by Sanofi/BMS. It was actually co-developed by Eli Lilly and Daiichi Sankyo. This post has been updated to reflect that.
- AstraZeneca has initiated a preclinical development program to develop a reversal antidote(MEDI2452) for Brilinta (ticagrelor), an oral platelet inhibitor used for secondary prevention of cardiovascular (CVD) events.
- Brilinta has been a key part of AZ's defense against a takeover by Pfizer as it forecases annual sales of $3.5 billion by 2023.
- Although the market is competitive,things are looking up for Brilinta. Third quarter sales were up 68% compared with last year, and the US Department of Justice just dropped an investigation into the pivotal trial that AZ used to win approval for Brilinta.
AZ's move could to make Brilinta reversible could make all the difference for the position of Brilinta among its peers, including Eli Lilly/Daiichi Sankyo's's Effient (prasugrel). With $127 million in third quarter sales, an increase of 68% compared with Q3 2013, the company is moving forward; however, it still needs to gain traction in the marketplace. For now, AZ is defensively positioning itself to stave off Pfizer's $118 billion takeover effort by looking into the future and aggressively developing its pipeline. MEDI2452 is an important part of that strategy.